Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasms

17 Oct 2018

Abstract excerpt

The classic Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem-cell diseases, characterized by activated JAK/STAT signaling and significant phenotypic mimicry, including a propensity for evolution to myeloid blast phase disease. Effective therapeutic options are limited for patients with Ph− MPNs in the blast phase (MPN-BP), and allogeneic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30333119
DOI: 10.1182/blood-2018-03-785907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How I treat the blast phase of Philadelphia chromosome–negative myeloproliferative neoplasmsPMID 30333119Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.Semantic proximity Read ↗

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adultsSemantic proximity Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.Semantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.Semantic proximity Read ↗

Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.Semantic proximity Read ↗

Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.